ImprimisRx® offers over 3,500 (over 200 formulations shown here) unique compounded formulations prescribed for many therapeutic areas. We are dedicated to providing medications to patients at affordable prices.
Don’t see what you are looking for? Click here to inquire about a customized formulation not in this list.
| Formulation | Classification | Strength |
|---|---|---|
| Ascorbic Acid* PF (Non-Corn) – 500mg/ml | Injection | 500mg/ml |
| Atropine Sulfate* – 5mL | Topical Medication | 0.025% |
| Atropine Sulfate* – 5mL | Topical Medication | 0.05% |
| Atropine Sulfate* – 5mL | Topical Medication | 0.01% |
| Brim-Dor® PF (Brimonidine/Dorzolamide)* – 10mL | Topical Medication | 0.15/2% |
| Buffered lidocaine hydrochloride PF 1%* – Single-use vial | Injectable | 1% |
| Buffered lidocaine hydrochloride PF 2%* – Single-use vial | Injectable | 2% |
| Dex-Moxi-Ketor®* – 1mL – Single Use Vial | Injectable | 1mg/0.5mg/0.4mg/mL |
| Dex-Moxi®* – 1mL – Single Use Vial | Injectable | 1mg/5mg/mL |
| Dimercaptopropane Sulfonate DMPS Preservative Free* – 50mg/ml | Injection | 50mg/ml |
| Dorzolamide PF* – 10mL | Topical Medication | 2% |
*For professional use only. ImprimisRx® Pharmacy specializes in customizing medications to meet unique patient and practitioner needs. ImprimisRx® dispenses only to individually identified patients with valid prescriptions. No compounded medication is reviewed by the FDA for safety or efficacy. ImprimisRx® does not compound copies of commercially available products. References available upon request.
Potential Ingredient Risks
Possible Indications: Prevention and treatment of scurvy, Treatment of symptoms of mild deficiency
Possible Adverse Effects: Hyperoxaluria (with large doses), Diarrhea, Dizziness, Fatigue, Flank pain, Flushing, Headache, Heartburn, Nausea, Vomiting
Potential Contraindications/Precautions: Oxalate nephropathy/nephrolithiasis; elderly patients and pediatric patients <2 years of age may be at increased risk. Patients with diabetes mellitus should not take excessive doses for extended periods of time. Hemolysis has been reported in patients with glucose-6-phosphatase dehydrogenase (G6PD) deficiency and the risk for severe hemolysis may be increased during ascorbic acid therapy. Use with caution in patients with hemochromatosis. Use with caution in patients with renal impairment or patients prone to recurrent renal calculi; may have increased risk of developing acute or chronic oxalate nephropathy. Elderly and Pediatric: Use with caution in the elderly and children <2; may be at increased risk for oxalate nephropathy.
Storage: Store at Room Temperature 20°C to 25°C (68°F to 77°F)
Auxiliary Labeling: Keep all medicines out of the reach of children. Minimize exposure to light because Ascorbic Acid solution is light sensitive. This Vial is a single dose preservative free vial. Discard unused portion. Throw away any medicine after the beyond use date.